Auxogyn – Advancing women’s reproductive health through novel scientific and clinical knowledge of early human developmental biology
- auxology (from Greek αὔξω, auxō, or αὐξάνω, auxanō, "growth") is a meta-term covering the study of human growth and biology
- gynaecology or gynecology (from Greek gynaikos meaning woman) is the medical practice dealing with the health of the female reproductive system. Literally, outside medicine, it means "the science of women".
Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into valuable clinical tools. The Company’s flagship product, the Eeva™ Test, is designed to deliver consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions.
Auxogyn was founded by pioneering scientists from the Stanford University (Professor Renee Reijo Pera, Ph.D. in collaboration with colleagues Dr. Barry Behr, Dr. Thomas Baer, and post-doctoral fellows Dr. Connie Wong and Dr. Kevin Loewke) who conducted landmark research that provided the first link between embryo developmental outcome, cell division events and the molecular health of the embryo. Auxogyn continues to provide new clinical and scientific benchmarks that reproductive endocrinologists and their patients can use when making critical decisions in their journey through infertility treatment.
Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One (venture capital arm of GlaxoSmithKline), and TPG Biotech.
Auxogyn’s first product, the non-invasive Early Embryo Viability Assessment System (Eeva), may improve in vitro fertilization (IVF) outcomes by providing IVF clinics and patients with objective information regarding embryo viability. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva’s quantitative data describing each embryo’s development, IVF clinics may improve the treatment path for their patients undergoing IVF procedures.
In addition to Eeva, Auxogyn is committed to developing other innovative products to address the growing number of patients suffering from infertility today.
CAUTION-Investigational Device. Limited by Federal (United States) law to investigational use.